Banyan BioInnovations
- Company typePrivate
- Founded2026
- HeadquartersBoston, United States
- Headcount—
- GTM typeB2B
- OfferingServices
Banyan BioInnovations firmographics
Firmographics- Name
- Banyan BioInnovations
- Legal name
- Banyan BioInnovations
- Website
- https://banyan-bio.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Ownership category
- akta.pro rank
Banyan BioInnovations industry classification
Industry- Product category
- Biotech Investment & Clinical-Stage Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
- akta.pro secondary industries
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)
Keywords
Where Banyan BioInnovations is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Banyan BioInnovations business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Investment Management / NewCo Formation: Banyan BioInnovations generates value by forming and developing asset-centric NewCos (clinical-stage companies) around best or first-in-class drug candidates. The firm deploys a veteran centralized development team and turnkey infrastructure to optimize clinical and regulatory execution. Success is driven by the failure of one program not bringing down the entire firm and success of one or two programs able to carry the portfolio. The model suggests carried interest and management fee revenue typical of investment firms.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Banyan BioInnovations product offering
Product offeringCore offering
Banyan BioInnovations is a life sciences investment firm that forms and develops asset-centric NewCos (newly created clinical-stage companies) around best or first-in-class drug candidates. It deploys a veteran centralized development team and turnkey infrastructure covering clinical strategy, regulatory planning, CMC, and clinical operations to advance each program through defined clinical and regulatory value inflection points, sourcing globally through Locust Walk's presence in the U.S., China, and Japan.
Product overview
Banyan BioInnovations is an investment firm powered by Locust Walk that operates as a differentiated model for clinical-stage value creation. The firm forms and develops asset-centric NewCos (newly created clinical-stage companies) around best or first-in-class drug candidates. The core offering is the NewCo Creation Model, supported by centralized development execution including clinical strategy, regulatory planning, CMC, and clinical operations. The firm leverages global sourcing presence in the U.S., China, and Japan, and provides turnkey infrastructure to optimize clinical and regulatory execution for each asset through key value inflection points.
Differentiator
Problem solved
Functional benefit
Products and services
- NewCo Creation Model A structured company-creation offering that forms and develops asset-centric NewCos (newly created clinical-stage companies) designed to reach defined clinical and regulatory value inflection points with discipline, capital efficiency, and institutional governance. Each NewCo has clear clinical objectives, disciplined and broad capitalization from launch, and access to world-class centralized operational infrastructure. The offering is targeted at biotech, pharma, and academic teams that need a disciplined execution partner for clinical-stage programs.
Companies that use Banyan BioInnovations
Customer profileSegments3 records
Ideal customer profiles3 records
Banyan BioInnovations technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Banyan BioInnovations partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Icon plcflagshipICON plc, a world-leading clinical research organization, is participating in Banyan BioInnovations through a strategic collaboration and investment. The partnership reflects a shared belief that close collaboration between sponsors and CROs can meaningfully improve the execution and efficiency of clinical development. ICON participated in the $100M+ commitment through strategic collaboration and investment, and the partnership supports clinical trial design for biotech development goals. This is a flagship partnership that provides Banyan Bio with world-class CRO capabilities for trial execution, design, and commercialization strategy.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Banyan BioInnovations competitors and assessment
Company assessmentBroad incumbents
- OrbiMed Advisors: Large healthcare-dedicated investment firm covering public and private biotech and pharma across all stages. Overlaps with Banyan in clinical-stage asset investment but at much broader scale.
- Blackstone Life Sciences: Multi-billion-dollar life sciences platform providing capital and development support to clinical-stage programs across therapeutic areas. Broader incumbent with overlapping clinical execution and asset-financing capabilities.
Emerging players
- Lengo Therapeutics: Clinical-stage biotech focused on developing precision oncology assets sourced from academic research — comparable emerging asset-centric clinical development approach.
- Curie.Bio: Founder-focused biotech company creation platform providing capital, operational support, and shared infrastructure for newly formed therapeutics companies — comparable emerging NewCo model.
- Formation Bio: Tech-enabled drug development company that acquires and develops clinical-stage assets with operational expertise. Comparable asset-centric acquisition and clinical execution focus.
Direct peers
- Roivant Sciences: Pioneer of the asset-centric NewCo model, spinning out Vants around clinical-stage pharma assets with centralized development infrastructure. Most direct comparable to Banyan's structural approach.
- BridgeBio Pharma: Asset-centric developer creating focused subsidiaries around genetic disease and clinical-stage programs with shared infrastructure — directly comparable hub-and-spoke clinical development model.
- Atlas Venture: Early-stage life sciences VC with a company-creation model that spins out biotechs from internal ideation and external sourcing — comparable venture-building approach to Banyan's NewCo model.
- Medicxi: Europe-based asset-centric life sciences investment firm that creates and develops single-asset companies around clinical-stage drug candidates, mirroring Banyan's NewCo formation thesis.
- RA Capital Management: Life sciences investment firm with both a public/private crossover fund and a company-creation arm (e.g., RA Capital-backed NewCos). Comparable dual focus on clinical-stage asset development and disciplined capitalization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Banyan BioInnovations social profiles
Digital presenceBanyan BioInnovations financial estimates
Financial estimateRevenue estimate
Valuation estimate
Banyan BioInnovations leadership team
Management profileNumber of profiles
Profiles2 records
Banyan BioInnovations funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Banyan BioInnovations M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Banyan BioInnovations
What does Banyan BioInnovations do?
Banyan BioInnovations is a life sciences investment firm that forms and develops asset-centric NewCos (newly created clinical-stage companies) around best or first-in-class drug candidates. It deploys a veteran centralized development team and turnkey infrastructure covering clinical strategy, regulatory planning, CMC, and clinical operations to advance each program through defined clinical and regulatory value inflection points, sourcing globally through Locust Walk's presence in the U.S., China, and Japan.
Is Banyan BioInnovations a public or private company?
Banyan BioInnovations is a private company. It is classified as venture growth investor backed and is currently operating.
When was Banyan BioInnovations founded?
Banyan BioInnovations was founded in 2026.
Where is Banyan BioInnovations based?
Banyan BioInnovations is headquartered in Boston, United States, in the North America region.
How does Banyan BioInnovations make money?
One revenue line is on record: investment Management / NewCo Formation.
Who are Banyan BioInnovations's main competitors?
Broad incumbents on record are OrbiMed Advisors and Blackstone Life Sciences. Emerging players are Lengo Therapeutics, Curie.Bio and Formation Bio. Direct peers are Roivant Sciences, BridgeBio Pharma, Atlas Venture, Medicxi and RA Capital Management.
Does Banyan BioInnovations have an API?
No public API is recorded for Banyan BioInnovations.
What industry is Banyan BioInnovations in?
Banyan BioInnovations's product category is Biotech Investment & Clinical-Stage Drug Development. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 541714 and its SIC code is 8731.